RXST Earnings Prediction
The chart below shows how RXST performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RXST sees a -3.46% change in stock price 10 days leading up to the earnings, and a +7.79% change 10 days following the report. On the earnings day itself, the stock moves by -0.23%. This data can give you a slight idea of what to expect for the next quarter's release.
RXST Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
35.31M
59.08%
1.22%
Gross Margin
71.42%
15.47%
2.75%
Operating Margin
-26.13%
-53.64%
9.38%
Net Margin
-17.95%
-67.91%
3.04%
EPS
-0.16
-54.29%
-0.00%
No Data Available
RXST Earnings Analysis
RxSight, Inc. Common Stock Corporation (RXST.O) Earnings Conference Call
Positive
Q3 Revenue Surge: 1. Significant Revenue Growth: RxSight generated Q3 2024 revenue of $35.3 million, a 59% increase compared to $22.2 million in Q3 2023, and a 1% increase from $34.9 million in Q2 2024.
LAL Sales Surge: 2. Strong LAL Sales Performance: The company sold 24,554 Light Adjustable Lenses (LALs) in Q3 2024, resulting in $24.2 million in LAL revenue, which is up 79% year-over-year and 2% sequentially.
Installed Base Expansion: 3. Increased Installed Base: The LDD installed base grew to 888 units, representing a 51% increase year-over-year and a 10% increase from Q2 2024, indicating strong demand for the product.
Gross Margin Improvement: 4. Improved Gross Margin: Gross margin for Q3 2024 was 71.4%, up from 61.9% in Q3 2023 and 69.5% in Q2 2024, reflecting a favorable product mix and lower costs.
Future Revenue Outlook: 5. Positive Guidance for Future Growth: The company raised its full-year 2024 revenue guidance to approximately $140 million, implying a year-over-year growth of about 57%, alongside an expected gross margin of 70% to 71%.
Negative
Rising Operating Expenses: 1. Increased Operating Expenses: SG&A expenses rose to $25.6 million, a 34% increase from $19.1 million in the same quarter last year, indicating rising costs that could impact profitability.
Net Loss Improvement: 2. Net Loss: The company reported a GAAP net loss of $6.3 million, or $0.16 per share, which, while improved from a loss of $12.4 million or $0.35 per share in Q3 2023, still reflects ongoing financial challenges.
Utilization Rate Decline: 3. Declining Average Monthly Utilization: Average monthly utilization of LALs per LDD decreased to 10.1 from 11 in the previous quarter, suggesting a slowdown in the rate of LAL procedures relative to installed LDDs.
Liquidity Reduction: 4. Cash Decrease: Cash, cash equivalents, and short-term investments fell to $207.1 million from $233.3 million at the end of Q2 2024, indicating a reduction in liquidity that could affect future operations.
Operating Expense Reduction: 5. Reduced Operating Expense Guidance: Full year 2024 operating expenses are now expected to be at the low end of the previously provided guidance of $135 million to $136 million, reflecting a potential cutback in spending that may hinder growth initiatives.
RXST FAQs
How does RXST typically perform around its earnings report dates?
Is RxSight, Inc. (RXST) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RXST Earning Call Sentiment
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RXST.O
3%Positive
The company reported strong revenue growth and improved gross margins. Despite increased SG&A expenses, the reduction in net loss and stable gross margins are positive indicators. The Q&A highlighted strong demand and stable pricing for products, with potential for market share growth. While there were some uncertainties, such as the impact of hurricanes and lack of clarity on 2025 guidance, overall sentiment remains positive. With a market cap of approximately $2.3 billion, the stock is likely to see a moderate positive reaction in the short term.